Texas based plasmid CMO VGXI breaks ground on facility expansion and new flex-scale GMP production plants. The Woodlands, TX – February 22, 2018 – VGXI announced today they have broken ground on a 5,000 square foot expansion of their Texas based manufacturing facility. Once complete, the project will increase the company’s footprint by 17% and… Read More »
Nominations are now open for the Vaccine Industry Excellence Awards of the 2018 World Vaccine Congress this April! Show your support for VGXI, Inc. by nominating us for the categories of “Best CMO” and “Best Production/Process Development“. Submit your nominations at the following link by 12Jan18: http://www.terrapinn.com/conference/world-vaccine-congress-washington/2018-ViE-Awards-Categories.stm
The Woodlands, TX, January 03, 2018: Learn more about Dorothy Peterson, VGXI’s VP of Operations, in a newly released publication by Voyage Houston Magazine. Follow this link to the full article: http://voyagehouston.com/interview/meet-dorothy-peterson-vgxi-inc-2700-research-forest-drive-suite-180-woodlands-tx-77381/
Stability of Plasmid DNA Products: A Review of the Data For any pharmaceutical product, an important consideration is the handling and environmental conditions that the material may experience from the time it is manufactured until final dosing of a patient. Plasmid DNA is generally recognized to have exceptional stability compared to other biologics such as… Read More »
GeneOne Life Science Receives Approval of IND by the Korean Ministry of Food and Drug Safety (KMFDS) of MERS-CoV Plasmid DNA vaccine, GLS-5300, for a Phase I/IIa Clinical Trial in Korea SEOUL, KOREA (PRWEB) September 17, 2017 GeneOne Life Science, Inc. announces that it has received approval from the South Korean Ministry of Food and Drug… Read More »
VGXI has reopened and we are getting back to normal operations. Our thoughts are with all those who have been affected by Hurricane Harvey, including our employees, their families, and all our neighbors in the area. For any who would like to contribute to the recovery effort, please consider a donation to one of the… Read More »
Update: VGXI will open for business on Thursday, August 31, 2017. To ensure the safety of our employees and their families, VGXI closed from Monday through Wednesday, August 28th – 30th, 2017. Please stay safe and check back on our website or facebook page for updates.
Heading to Paris in October? Meet with representatives from VGXI and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. 2017 International Society of Vaccines Annual Congress October 5 – 7, 2017 Institute Pasteur Paris, France
Did you miss us at ASGCT? Download our poster at the link below: Novel Method for RNA Quantification and Exclusion from Plasmid DNA Vector Purification Process Stream Presented on Thursday, May 11, 2017 from 5:15 pm – 7:15 pm Session Information: Vector and Cell Engineering and Manufacturing Location: Exhibit Hall C & B South Abstract #484… Read More »
VGXI announced that on April 10th, 2017 the corporation won the award for Best Production / Process Development at the 10th Annual ViE Awards Ceremony held at the 2017 World Vaccine Congress in Washington, D.C.
Votes are still being accepted for the shortlist of companies in each category! Show your support for VGXI by supporting us in the category of “Best Contract Manufacturing Organization” AND “Best Production/Process Development” for the Vaccine Industry Excellence Awards. Winners will be announced at the World Vaccine Congress in Washington DC in April, 2017. Follow this link to… Read More »
On November 18, 2016 VGXI hosted a roundtable discussion with US Congressman Pete Olson and key biotech industry leaders. From left: U.S. Congressman Pete Olson; Ann Tanabe, CEO of BioHouston; Young Park, CEO of GeneOne Life Science; Jim Greenwood, President of BIO; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO… Read More »